Latest Revenue Guidance News

Page 4 of 30
Oakridge International reported a $267,000 operating cash outflow for the September quarter, leaving $343,000 in cash and an estimated 1.28 quarters of funding. The healthcare technology company expects collections and customer orders to improve cash flow, while evaluating additional funding and continuing to manage a potential historical claim from Teko International.
Victor Sage
Victor Sage
30 Oct 2026
Synertec Corporation (ASX: SOP) has entered FY27 with $74.3 million of contracted work-in-hand, up 395% on the prior year, while maintaining revenue guidance of $37.5 million to $40.0 million. Revenue rose 18% in the first quarter and monthly EBITDA reached breakeven in September, although cash remained under pressure as project delivery accelerated.
Victor Sage
Victor Sage
30 Oct 2026
Way2VAT is betting that its new Way2Invoice platform, Coupa distribution and Go-Global partnership can convert product momentum into recurring revenue, while a 15% cost reduction begins to address ongoing cash burn. Quarterly revenue was broadly flat at A$1.90 million, with A$3.05 million in cash and A$5.20 million of debt drawn at quarter end.
Victor Sage
Victor Sage
30 Oct 2026
TALi Digital closed its September quarter with $3.9 million in cash after completing a $3.3 million capital raise and winning shareholder approval for the Datasphere transaction. The company has also exercised an option to negotiate exclusive worldwide rights to Technion in-memory computing technology, although the licence remains unsigned and the technology unproven at commercial scale.
Victor Sage
Victor Sage
30 Oct 2026
Helia’s nine-month statutory profit fell to $136.5 million as weaker lending, the loss of its CBA contract and softer housing conditions reduced revenue. Claims remain low and capital coverage strengthened, allowing the mortgage insurer to retain its FY26 guidance.
Victor Sage
Victor Sage
30 Oct 2026
Saluda Medical delivered a strong operational start to FY27, with US implants up 55% and quarterly revenue rising 26% to US$23.1 million. But the medical device company ended September with US$73.6 million in cash, US$100 million of secured debt drawn and estimated funding for just 2.3 quarters at the quarter’s cash-use rate.
Ada Torres
Ada Torres
29 Oct 2026
Appen has delivered its strongest quarterly result of FY26, with revenue rising 34% to US$73.9 million and underlying EBITDA increasing more than tenfold to US$10.3 million. Appen Global returned to profit while China continued to drive growth, although FY26 revenue is expected to land in the lower half of guidance.
Victor Sage
Victor Sage
29 Oct 2026
Vinyl Group delivered record Q1 FY27 revenue of A$6.33 million and entered the December quarter with record bookings, but ended September with only A$777,000 in cash and 0.45 quarters of reported funding. The company has increased chairman Ken Gaunt’s unsecured facility by A$2 million while it works to collect more than A$5 million in receivables.
Victor Sage
Victor Sage
29 Oct 2026
Titomic has strengthened its balance sheet with A$16.5 million in new equity and approval for a further US$10.3 million EXIM loan, while reporting more than A$11.8 million in orders since September. The progress comes with a sharper funding test: quarter-end cash was A$18.1 million after a A$10.4 million operating outflow, and the EXIM facility remains undrawn.
Victor Sage
Victor Sage
29 Oct 2026
IMEXHS has moved several proprietary AI agents into live customer use while delivering stronger revenue, earnings and operating cash flow in the third quarter. But software bookings fell sharply, ARR was flat after churn, and Colombian receivables remain a material cash risk.
Victor Sage
Victor Sage
28 Oct 2026
Audeara has moved two AI noise reduction licensing programs into commercial production, helping lift quarterly revenue 37.7% while initial orders remain modest. The milestone arrives alongside A$247,000 in cash, a A$1.292 million operating outflow and a pending A$505,000 placement tranche.
Victor Sage
Victor Sage
28 Oct 2026
LTR Pharma has moved ROXUS from signed US commercial agreements to its first fulfilled patient-specific prescriptions, while SPONTAN’s final Phase II report completes the pharmacokinetic dataset agreed with the FDA. The company ended September with A$18.2 million in cash and no debt.
Victor Sage
Victor Sage
28 Oct 2026

Browse the archive

Full archive